Company / Working Capital
Zivo Bioscience, Inc. Working Capital History
FY2013-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
-$406.4K
FY2024
5-year range
-$11.2M / $6.0M
FY2020-FY2024
Trend
+82.6%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital returned to growth in FY2024 after 2 years of decline, reaching -$406,380.
Based on SEC 10-K filings.
-$406,380 in FY2024.
Declined from -$126,043 to -$406,380 over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, working capital increased 82.6% year-over-year.
- Peak working capital was recorded in FY2021.
- Lowest working capital in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -96.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$406.4K | +82.6% |
| FY2023 | -$2.3M | -1753.5% |
| FY2022 | -$126.0K | -102.1% |
| FY2021 | $6.0M | +153.6% |
| FY2020 | -$11.2M | -34.6% |
| FY2019 | -$8.3M | +21.8% |
| FY2016 | -$10.7M | -115.7% |
| FY2015 | -$4.9M | +20.3% |
| FY2014 | -$6.2M | +39.1% |
| FY2013 | -$10.2M | -211.5% |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026